The distribution of IIM subtypes showed dermatomyositis as the most common (78.9%), followed by polymyositis (57.9%), inclusion body myositis (15.8%), and immune-mediated necrotizing myopathy (5.3%).

The RESET-Myositis and RESET-SLE trials were designed ... representing a May 28 data cut from two patients with immune-mediated necrotizing myopathy and SLE, indicated a well-tolerated safety ...

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...